SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- News Corp. Beats Estimates on Studio, Cable Strength

TOP HEADLINES

» Markets | Economy | Companies

- Credit Suisse Shares Fall on Surprise Fourth-Quarter Loss

PHARMA'S MARKET VIDEO

» More

Wall Street Protests 29 Apr 2010
Following a big demonstration in favor of financial regulation right outside the NYSE, with CNBC's Mike Huckman.
March on Wall Street 29 Apr 2010
Main Street takes to Wall Street today with thousands of union community activists marching to make the big banks pay, with CNBC's Mike Huckman.
Mike Huckman: Reporter's Reporter 29 Apr 2010
Original air date, June 26, 2002.
SBUX Beats the Street 21 Apr 2010
CNBC's Mike Huckman has Starbucks' earnings breakdown.

The Orange Squeeze on Dimon

16 Apr 2010

Some students at Syracuse University have a different idea rather than having JPMorgan's chairman/CEO Jamie Dimon deliver this year's commencement speech, reports CNBC's Mike Huckman.

Nasdaq Outperforms 14 Apr 2010
The Nasdaq easily outperforming the other major indexes today, with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

Pharma's Market

Text Size

Feb.17

1:45 PM ET

Tuesday, 17 Feb 2009

Stem Cells Sell

Posted By:Mike Huckman

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Osiris Therapeutics Inc | Celgene Corp | Cytori Therapeutics Inc

AP
An article in the business section of today's "New York Times" talks about tighter travel budgets resulting in lower attendance at some big destination conferences. Many meetings have also been canceled not so much due to money, but appearances—especially for companies that got TARP dollars.

But here at the 4th Annual Stem Cell Summit I'm told attendance is up. By about 50 percent, no less, over last year.

All day long privately-held and publicly-traded companies are presenting to around 250 investors.

The meeting may be drawing greater interest because of widespread media reports that President Obama will soon lift the federal funding ban on new embryonic stem cell research. In fact, in anticipation of a Democrat winning last year, stem cell stocks overall were up five percent.

The veteran financial analyst, Robin Young, who owns the company that puts on the summit, says the stem cell market and stem cell market caps are poised to soar.

He forecasts stem cell revenue will climb from $62 million last year to $8.2 billion by 2018. And he believes that growth will spur stem cell stock market caps from a total of $1.7 billion last year to between $22 billion and $49 billion over the next 10 years.

But Young cautions it won't be a straight line up. There's been a stem cell bubble before and he expects at least a couple more. He recommends investors with a long-term horizon buy a basket of stem cell stocks, many of which he calls "cheap" right now.

I'm not going to mention them all here because some of them are super small. But among the ones I've reported on recently and have highlighted in my coverage today are Geron [GERN Loading... () ], Celgene [CELG Loading... () ], Osiris [OSIR Loading... () ] and Cytori [CYTX Loading... () ].